A coalition of stakeholders from across the lifecycle of medicines development has emphasised the need to bring together leadership at a global level to ensure that patient engagement becomes the norm. Members of Patient Focused Medicines Development (PFMD) have shared their views in a recent video highlighting the benefits of global collaboration in patient engagement.

PFMD member Nicola Bedlington, Secretary General at European Patients’ Forum says: “Bringing together leadership from diverse stakeholders at a global level will help to ensure that patient engagement across the lifecycle of medicines development is seen as the norm.”

Tony Hoos, Head of Medical for Europe at Amgen explains: “We can only achieve meaningful patient engagement in medicines development if we work together in a non-competitive way to set standards, develop frameworks, and have a  ‘harmonised code’ of how we want to work with patients.”

Paul Robinson Director of Patient Perspectives, Merck says: “We are all sharing our successes, we are sharing our failures, and we will move the whole medicines development process forward as a result of our efforts.”

Watch the video interview to find out more.


PFMD welcomes membership from institutions, organisations and enterprises committed to better patient engagement in the lifecycle of medicines and a better future for patients. Join us and help shape the patient engagement landscape